Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Eric Wu

Concepts (464)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
31
2022
423
4.030
Why?
Hyperkalemia
4
2021
35
2.440
Why?
Everolimus
10
2016
112
2.260
Why?
Health Resources
10
2026
131
2.240
Why?
Cost of Illness
13
2022
323
1.950
Why?
Health Services
11
2016
112
1.450
Why?
Breast Neoplasms
16
2018
2418
1.430
Why?
Antineoplastic Agents
20
2018
2219
1.390
Why?
Citalopram
6
2012
33
1.180
Why?
Receptors, Antigen, T-Cell
4
2021
677
1.110
Why?
Receptors, Estrogen
3
2015
406
1.100
Why?
Health Expenditures
9
2020
198
1.090
Why?
Medication Adherence
4
2015
535
1.030
Why?
Psoriasis
5
2018
110
0.980
Why?
Immunotherapy, Adoptive
2
2020
356
0.940
Why?
Insurance Claim Review
18
2017
87
0.930
Why?
Practice Patterns, Physicians'
6
2018
1408
0.920
Why?
United States
52
2022
16136
0.910
Why?
Hepatitis C, Chronic
3
2019
150
0.900
Why?
Pyrimidines
7
2014
532
0.860
Why?
Renal Insufficiency, Chronic
3
2021
640
0.860
Why?
Drug Substitution
3
2019
62
0.850
Why?
Piperazines
6
2014
368
0.850
Why?
Middle Aged
76
2026
36619
0.840
Why?
Biosimilar Pharmaceuticals
2
2022
28
0.840
Why?
Receptors, Progesterone
2
2015
242
0.810
Why?
Attention Deficit Disorder with Hyperactivity
4
2012
422
0.780
Why?
Aged
57
2026
26432
0.760
Why?
Models, Economic
2
2020
63
0.760
Why?
Retrospective Studies
46
2026
17438
0.760
Why?
Comparative Effectiveness Research
3
2012
171
0.740
Why?
Benzamides
6
2014
226
0.740
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
2014
128
0.730
Why?
Antifungal Agents
4
2017
153
0.720
Why?
Humans
123
2026
146342
0.720
Why?
Cost-Benefit Analysis
15
2022
640
0.710
Why?
Imatinib Mesylate
7
2014
77
0.700
Why?
Female
93
2026
79499
0.690
Why?
Central Nervous System Stimulants
3
2012
183
0.680
Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
195
0.660
Why?
Hospital Costs
3
2020
131
0.650
Why?
Gout
2
2012
34
0.650
Why?
Rheumatology
1
2022
136
0.640
Why?
Acidosis
1
2021
105
0.630
Why?
Adult
58
2026
41087
0.630
Why?
Male
79
2026
73396
0.630
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
299
0.620
Why?
Proportional Hazards Models
14
2017
1331
0.610
Why?
Hypoglycemic Agents
4
2015
1412
0.610
Why?
Kaplan-Meier Estimate
12
2018
970
0.610
Why?
Nocturia
1
2019
8
0.610
Why?
Antibodies, Monoclonal
7
2018
1512
0.590
Why?
Antineoplastic Combined Chemotherapy Protocols
11
2018
1998
0.590
Why?
Databases, Factual
13
2021
1493
0.580
Why?
Prevalence
11
2021
2861
0.580
Why?
Postmenopause
7
2018
394
0.570
Why?
Comorbidity
12
2014
1665
0.550
Why?
Hospitalization
15
2021
2475
0.540
Why?
Medicare
10
2022
920
0.530
Why?
Nutrition Surveys
1
2019
270
0.530
Why?
Proline
2
2015
79
0.530
Why?
Candida
2
2017
46
0.520
Why?
Leukemia, Myeloid, Chronic-Phase
2
2014
3
0.520
Why?
Fluconazole
1
2017
24
0.510
Why?
Candidemia
1
2017
16
0.500
Why?
Protein Kinase Inhibitors
5
2014
983
0.500
Why?
Cardiologists
1
2017
45
0.500
Why?
Myocardial Perfusion Imaging
1
2017
50
0.490
Why?
Fees, Pharmaceutical
3
2016
8
0.490
Why?
Tomography, Emission-Computed, Single-Photon
1
2017
104
0.490
Why?
Oligopeptides
2
2015
264
0.480
Why?
Aftercare
2
2021
225
0.470
Why?
Thrombolytic Therapy
1
2017
165
0.470
Why?
Diabetes Mellitus, Type 2
5
2015
2623
0.470
Why?
Cystitis, Interstitial
2
2006
20
0.470
Why?
Biological Therapy
1
2016
30
0.460
Why?
Antidepressive Agents, Second-Generation
3
2011
44
0.460
Why?
Antirheumatic Agents
2
2016
309
0.460
Why?
Antiviral Agents
3
2019
779
0.450
Why?
Neoplasm Recurrence, Local
4
2026
1160
0.450
Why?
Drug Eruptions
1
2015
28
0.440
Why?
Tissue Plasminogen Activator
1
2017
245
0.440
Why?
Propylamines
2
2012
11
0.430
Why?
Costs and Cost Analysis
10
2019
217
0.430
Why?
Physicians, Primary Care
1
2017
210
0.420
Why?
Methylphenidate
2
2012
48
0.420
Why?
Fibrinolytic Agents
1
2017
303
0.420
Why?
Gastrointestinal Stromal Tumors
1
2014
41
0.410
Why?
Diphosphonates
2
2012
68
0.410
Why?
Delivery of Health Care
2
2019
947
0.410
Why?
Health Care Rationing
2
2016
54
0.410
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
344
0.410
Why?
Insulin
3
2015
2525
0.410
Why?
Patient Acceptance of Health Care
8
2026
881
0.400
Why?
Anemia
1
2015
190
0.390
Why?
Brain Ischemia
1
2017
362
0.390
Why?
Treatment Outcome
24
2021
11821
0.390
Why?
Imidazoles
2
2012
245
0.390
Why?
Hypertension
5
2018
1272
0.380
Why?
Neoplasm Metastasis
8
2018
693
0.380
Why?
Insurance, Health
5
2011
318
0.380
Why?
Dextroamphetamine
1
2012
4
0.370
Why?
Guanfacine
1
2012
5
0.360
Why?
Aged, 80 and over
14
2020
8391
0.360
Why?
Antineoplastic Agents, Hormonal
4
2016
196
0.360
Why?
Pharmacoepidemiology
1
2012
24
0.360
Why?
Liver Neoplasms
2
2015
776
0.350
Why?
Attention Deficit and Disruptive Behavior Disorders
1
2012
46
0.350
Why?
Patient Compliance
3
2011
589
0.340
Why?
Medicaid
3
2012
477
0.340
Why?
Pulmonary Embolism
1
2014
246
0.340
Why?
Drug Delivery Systems
1
2015
377
0.340
Why?
Schizophrenia
2
2006
537
0.340
Why?
Drug Costs
6
2015
116
0.330
Why?
Fumarates
1
2011
10
0.330
Why?
Disease-Free Survival
7
2019
778
0.330
Why?
Antibodies, Monoclonal, Humanized
9
2018
992
0.330
Why?
Drugs, Generic
1
2011
28
0.330
Why?
Bone Diseases
1
2011
60
0.320
Why?
Referral and Consultation
1
2017
881
0.320
Why?
Amides
1
2011
100
0.310
Why?
Angiotensin Receptor Antagonists
1
2011
115
0.310
Why?
Triazoles
4
2016
190
0.310
Why?
Stroke
2
2017
1287
0.300
Why?
Drug Monitoring
4
2016
399
0.300
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
228
0.300
Why?
Venous Thromboembolism
1
2014
332
0.300
Why?
Arthritis, Rheumatoid
2
2016
1185
0.290
Why?
Tumor Necrosis Factor-alpha
5
2022
1224
0.290
Why?
Crohn Disease
5
2012
250
0.290
Why?
Potassium
2
2021
151
0.290
Why?
Sick Leave
2
2007
16
0.290
Why?
Heart Failure
3
2020
2329
0.290
Why?
Diabetes Mellitus
1
2018
1101
0.290
Why?
Hyperuricemia
1
2009
47
0.290
Why?
Myelodysplastic Syndromes
2
2021
170
0.280
Why?
Anticoagulants
1
2014
746
0.270
Why?
Oligonucleotides
2
2019
155
0.270
Why?
Absenteeism
2
2005
51
0.270
Why?
Uric Acid
1
2009
167
0.270
Why?
Quality of Life
9
2021
3200
0.260
Why?
Risk Factors
12
2017
10921
0.260
Why?
Insurance Claim Reporting
2
2007
25
0.260
Why?
Multiple Myeloma
1
2011
310
0.260
Why?
Randomized Controlled Trials as Topic
3
2012
1763
0.250
Why?
Physicians
1
2015
955
0.250
Why?
Head and Neck Neoplasms
1
2012
563
0.250
Why?
Hypoglycemia
1
2012
490
0.240
Why?
Health Status Indicators
1
2007
167
0.240
Why?
Leukemia, Myeloid, Acute
2
2026
702
0.240
Why?
Young Adult
14
2026
14330
0.240
Why?
Drug Therapy, Combination
6
2019
1036
0.240
Why?
Pentosan Sulfuric Polyester
1
2006
2
0.230
Why?
Economics, Pharmaceutical
1
2006
10
0.230
Why?
Drug Resistance, Fungal
2
2017
8
0.230
Why?
Treatment Failure
3
2017
361
0.230
Why?
fms-Like Tyrosine Kinase 3
1
2026
52
0.230
Why?
Endometriosis
2
2017
58
0.220
Why?
Adolescent
22
2026
22557
0.220
Why?
Urinary Incontinence
1
2005
65
0.210
Why?
Prostatic Neoplasms
2
2012
972
0.210
Why?
Diagnostic Errors
1
2006
178
0.210
Why?
Nitriles
3
2016
212
0.210
Why?
Immunoglobulin G
1
2008
901
0.210
Why?
Recurrence
3
2020
1133
0.200
Why?
Electronic Health Records
2
2021
1210
0.190
Why?
Protein-Tyrosine Kinases
4
2014
429
0.190
Why?
Emergency Service, Hospital
4
2021
2363
0.190
Why?
Psychotic Disorders
1
2005
188
0.190
Why?
Antihypertensive Agents
3
2012
519
0.190
Why?
Molecular Targeted Therapy
3
2015
447
0.180
Why?
Genetic Therapy
2
2021
303
0.180
Why?
Thiophenes
2
2014
117
0.170
Why?
Infliximab
1
2022
107
0.170
Why?
Population Surveillance
1
2005
481
0.170
Why?
Delayed-Action Preparations
3
2017
192
0.170
Why?
Anti-Inflammatory Agents
3
2011
474
0.170
Why?
Giant Cell Tumor of Tendon Sheath
1
2021
9
0.170
Why?
Bone Density Conservation Agents
2
2012
83
0.170
Why?
Gout Suppressants
2
2012
18
0.170
Why?
Gastritis
1
2022
117
0.160
Why?
Enteritis
1
2022
105
0.160
Why?
Carcinoma, Non-Small-Cell Lung
3
2015
1195
0.160
Why?
Polymerase Chain Reaction
2
2014
1031
0.160
Why?
Severity of Illness Index
6
2018
2921
0.160
Why?
Biological Products
2
2016
258
0.160
Why?
Hemophilia B
1
2021
65
0.160
Why?
Atomoxetine Hydrochloride
2
2012
8
0.160
Why?
Antimetabolites, Antineoplastic
1
2021
108
0.160
Why?
Bronchodilator Agents
2
2011
186
0.160
Why?
Adenocarcinoma
1
2007
927
0.150
Why?
Time Factors
5
2017
7109
0.150
Why?
Immunologic Factors
1
2022
244
0.150
Why?
Voriconazole
2
2016
21
0.150
Why?
Eosinophilia
1
2022
224
0.150
Why?
National Health Programs
1
2019
23
0.150
Why?
Regression Analysis
4
2012
999
0.150
Why?
Technology Assessment, Biomedical
1
2019
44
0.150
Why?
Pulmonary Disease, Chronic Obstructive
3
2011
928
0.150
Why?
Aromatase Inhibitors
2
2018
81
0.150
Why?
Hemophilia A
1
2021
150
0.150
Why?
Muscular Atrophy, Spinal
1
2019
31
0.150
Why?
Atrial Fibrillation
1
2005
560
0.150
Why?
Survival of Motor Neuron 1 Protein
1
2019
12
0.140
Why?
Patient Readmission
2
2017
778
0.140
Why?
Health Services Research
1
2021
390
0.140
Why?
Spinal Muscular Atrophies of Childhood
1
2019
20
0.140
Why?
Survival Analysis
4
2018
1378
0.140
Why?
Multivariate Analysis
5
2015
1543
0.140
Why?
Microbial Sensitivity Tests
2
2017
367
0.140
Why?
Urologic Neoplasms
1
2018
31
0.140
Why?
China
2
2021
280
0.140
Why?
Idiopathic Pulmonary Fibrosis
2
2015
697
0.140
Why?
Europe
3
2019
421
0.130
Why?
Vital Capacity
2
2015
293
0.130
Why?
Aging
1
2009
1996
0.130
Why?
Polystyrenes
1
2018
38
0.130
Why?
Managed Care Programs
2
2010
137
0.130
Why?
Antidepressive Agents
2
2011
235
0.130
Why?
Chronic Disease
4
2014
1827
0.130
Why?
Time-to-Treatment
2
2017
257
0.130
Why?
4-Aminopyridine
1
2017
30
0.130
Why?
Retreatment
1
2017
79
0.130
Why?
Overweight
1
2022
614
0.130
Why?
Thiazoles
2
2014
139
0.120
Why?
Drug Administration Schedule
4
2013
790
0.120
Why?
Aspergillosis
1
2016
24
0.120
Why?
Chemotherapy, Adjuvant
2
2016
429
0.120
Why?
Patient Preference
1
2019
226
0.120
Why?
Abiraterone Acetate
1
2016
15
0.120
Why?
Consumer Behavior
1
2017
68
0.120
Why?
Administration, Intravenous
1
2017
172
0.120
Why?
Hysterectomy
1
2017
139
0.120
Why?
Administrative Claims, Healthcare
1
2016
29
0.120
Why?
Mental Disorders
1
2005
1148
0.120
Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
54
0.120
Why?
Capecitabine
1
2016
56
0.120
Why?
Disability Evaluation
1
2017
297
0.110
Why?
Trastuzumab
1
2016
119
0.110
Why?
Prednisone
1
2016
229
0.110
Why?
Clinical Protocols
1
2017
282
0.110
Why?
Androstadienes
1
2015
77
0.110
Why?
Ki-1 Antigen
1
2015
7
0.110
Why?
Patient Admission
1
2017
216
0.110
Why?
International Classification of Diseases
1
2016
142
0.110
Why?
Waiting Lists
1
2017
251
0.110
Why?
Logistic Models
2
2014
2126
0.110
Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
23
0.110
Why?
Patient Discharge
1
2021
997
0.110
Why?
Ribavirin
1
2015
81
0.110
Why?
Drug Interactions
1
2016
405
0.110
Why?
Ambulatory Care
3
2015
628
0.110
Why?
Neoplasm Staging
2
2015
1488
0.100
Why?
California
2
2006
475
0.100
Why?
Carboplatin
1
2014
168
0.100
Why?
International Normalized Ratio
1
2014
55
0.100
Why?
Heparin, Low-Molecular-Weight
1
2014
37
0.100
Why?
Amphotericin B
1
2014
36
0.100
Why?
Cytogenetic Analysis
1
2013
34
0.100
Why?
Recombinant Proteins
1
2017
1361
0.100
Why?
Insurance, Health, Reimbursement
1
2014
97
0.100
Why?
Japan
3
2021
149
0.100
Why?
Models, Theoretical
1
2017
561
0.100
Why?
Cross-Sectional Studies
3
2019
5899
0.100
Why?
Follow-Up Studies
5
2015
5439
0.100
Why?
Constipation
1
2014
98
0.100
Why?
Drug Prescriptions
1
2015
314
0.100
Why?
Paclitaxel
1
2014
260
0.100
Why?
Morpholines
1
2014
130
0.100
Why?
ErbB Receptors
2
2016
636
0.100
Why?
Receptor Protein-Tyrosine Kinases
1
2015
227
0.100
Why?
Immunoconjugates
1
2015
138
0.100
Why?
Mycoses
1
2014
87
0.100
Why?
Budgets
1
2012
14
0.090
Why?
Recovery of Function
1
2017
725
0.090
Why?
Hodgkin Disease
1
2015
173
0.090
Why?
Drug Combinations
2
2011
400
0.090
Why?
Allopurinol
1
2012
70
0.090
Why?
Adalimumab
5
2011
53
0.090
Why?
Warfarin
1
2014
179
0.090
Why?
Cohort Studies
5
2016
6077
0.090
Why?
Lisdexamfetamine Dimesylate
1
2012
8
0.090
Why?
New Zealand
1
2012
56
0.090
Why?
Laparoscopy
1
2017
487
0.090
Why?
Immunocompromised Host
1
2014
201
0.090
Why?
Ethanolamines
1
2012
14
0.090
Why?
Gastrointestinal Diseases
1
2014
220
0.090
Why?
Pyridines
1
2016
610
0.090
Why?
Health Status
2
2008
827
0.090
Why?
Databases as Topic
2
2009
70
0.090
Why?
Multiple Sclerosis
1
2017
435
0.090
Why?
Benzopyrans
1
2012
31
0.090
Why?
Clinical Trials as Topic
2
2019
1064
0.090
Why?
Genetic Testing
1
2015
492
0.090
Why?
Estradiol
1
2015
517
0.090
Why?
Triple Negative Breast Neoplasms
1
2014
220
0.090
Why?
Florida
1
2012
117
0.090
Why?
Sulfonylurea Compounds
1
2012
49
0.090
Why?
Rivaroxaban
1
2014
270
0.090
Why?
Pleural Effusion
1
2012
59
0.090
Why?
Surveys and Questionnaires
4
2021
6073
0.080
Why?
North America
1
2012
300
0.080
Why?
Neurotransmitter Uptake Inhibitors
1
2011
3
0.080
Why?
Fractures, Spontaneous
1
2011
15
0.080
Why?
Australia
1
2012
291
0.080
Why?
Cyclohexanols
1
2011
9
0.080
Why?
Lung Neoplasms
2
2015
2675
0.080
Why?
Hypercalcemia
1
2011
23
0.080
Why?
Child
6
2020
22693
0.080
Why?
Nebulizers and Vaporizers
1
2011
63
0.080
Why?
Spinal Cord Compression
1
2011
24
0.080
Why?
Drug Resistance, Neoplasm
2
2026
893
0.080
Why?
Sirolimus
1
2012
282
0.080
Why?
Cost Sharing
1
2011
23
0.080
Why?
Efficiency
2
2011
102
0.080
Why?
Adamantane
1
2011
18
0.080
Why?
Models, Statistical
2
2012
669
0.080
Why?
Bone Diseases, Metabolic
1
2011
60
0.080
Why?
Case-Control Studies
3
2014
3647
0.080
Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2011
46
0.080
Why?
Communication
1
2017
980
0.080
Why?
Norepinephrine
1
2011
201
0.080
Why?
Health Benefit Plans, Employee
2
2009
25
0.080
Why?
Bone Neoplasms
1
2012
272
0.080
Why?
Pyrazines
1
2011
94
0.080
Why?
Pyrrolidines
1
2011
127
0.080
Why?
Angiogenesis Inhibitors
1
2011
239
0.070
Why?
Linear Models
1
2012
857
0.070
Why?
Gastrointestinal Agents
1
2009
63
0.070
Why?
Administration, Oral
1
2012
872
0.070
Why?
Etanercept
1
2008
60
0.070
Why?
Drug Utilization
1
2010
171
0.070
Why?
Serotonin
1
2011
297
0.070
Why?
Blood Chemical Analysis
1
2009
109
0.070
Why?
Obesity
1
2022
3131
0.070
Why?
Depressive Disorder
1
2011
361
0.070
Why?
Receptors, Tumor Necrosis Factor
1
2008
162
0.070
Why?
Age Distribution
3
2015
399
0.070
Why?
Amphetamines
1
2007
6
0.070
Why?
Adrenergic Uptake Inhibitors
1
2007
14
0.070
Why?
Insurance, Pharmaceutical Services
1
2007
23
0.060
Why?
Employment
2
2007
180
0.060
Why?
Digestive System Surgical Procedures
1
2008
115
0.060
Why?
Medical Audit
1
2007
78
0.060
Why?
Quality-Adjusted Life Years
2
2022
122
0.060
Why?
Age Factors
3
2015
3347
0.060
Why?
Veterans Disability Claims
1
2006
4
0.060
Why?
Disease Progression
4
2015
2867
0.060
Why?
Algorithms
1
2014
1849
0.060
Why?
Laboratories
1
2007
109
0.060
Why?
Private Sector
1
2006
50
0.060
Why?
Employer Health Costs
1
2005
3
0.060
Why?
Coronary Disease
1
2008
380
0.060
Why?
Ischemic Attack, Transient
1
2006
71
0.060
Why?
Metabolic Diseases
1
2007
114
0.060
Why?
Mexico
1
2026
233
0.060
Why?
Hallucinations
1
2005
33
0.060
Why?
Atrial Flutter
1
2005
47
0.050
Why?
Asthma
2
2007
1800
0.050
Why?
Double-Blind Method
4
2011
2070
0.050
Why?
Area Under Curve
1
2005
335
0.050
Why?
Administration, Inhalation
3
2011
567
0.050
Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
224
0.050
Why?
Adrenal Cortex Hormones
1
2007
486
0.050
Why?
Dasatinib
2
2014
58
0.050
Why?
Metabolic Syndrome
1
2007
364
0.050
Why?
Anti-Asthmatic Agents
1
2006
263
0.050
Why?
Data Collection
1
2006
650
0.050
Why?
Body Weight
1
2007
968
0.050
Why?
Psychiatric Status Rating Scales
1
2005
522
0.050
Why?
Colorectal Neoplasms
1
2011
874
0.050
Why?
Lung
1
2015
4122
0.050
Why?
Bevacizumab
2
2014
169
0.040
Why?
Health Policy
1
2005
399
0.040
Why?
Diagnosis, Differential
1
2006
1503
0.040
Why?
Interviews as Topic
1
2005
930
0.040
Why?
Dose-Response Relationship, Drug
3
2011
2022
0.040
Why?
Veterans
1
2013
1650
0.040
Why?
Information Storage and Retrieval
1
2021
121
0.040
Why?
Glucagon-Like Peptides
1
2022
76
0.040
Why?
Mental Health Services
1
2005
450
0.040
Why?
Infant
4
2019
10114
0.040
Why?
Hematopoietic Stem Cell Transplantation
1
2026
704
0.040
Why?
Asia
1
2019
69
0.040
Why?
Azacitidine
1
2021
168
0.040
Why?
Remission Induction
2
2011
308
0.040
Why?
France
1
2019
40
0.040
Why?
Spain
1
2019
50
0.040
Why?
Incidence
1
2006
2936
0.040
Why?
Reproducibility of Results
1
2007
3416
0.040
Why?
Italy
1
2019
118
0.040
Why?
Germany
1
2019
139
0.040
Why?
Cyclin-Dependent Kinase 4
1
2018
52
0.030
Why?
Sex Factors
2
2015
2107
0.030
Why?
Neutropenia
1
2018
153
0.030
Why?
Potassium Channel Blockers
1
2017
47
0.030
Why?
Disease Management
2
2015
651
0.030
Why?
Models, Econometric
1
2016
35
0.030
Why?
Bayes Theorem
1
2019
426
0.030
Why?
Veterans Health
1
2018
188
0.030
Why?
Itraconazole
1
2016
8
0.030
Why?
B-Lymphocytes
1
2020
887
0.030
Why?
Antineoplastic Protocols
1
2014
6
0.030
Why?
Utilization Review
1
2014
39
0.030
Why?
Early Diagnosis
1
2015
251
0.030
Why?
Cardiovascular Diseases
1
2007
2219
0.030
Why?
Forced Expiratory Volume
1
2015
451
0.030
Why?
Aspergillus
1
2014
18
0.030
Why?
Gene Rearrangement
1
2015
156
0.030
Why?
Hypothyroidism
1
2014
68
0.030
Why?
Genes, abl
1
2013
4
0.030
Why?
Cryptococcus
1
2014
16
0.030
Why?
Medication Therapy Management
1
2014
73
0.030
Why?
Anemia, Iron-Deficiency
1
2014
61
0.030
Why?
Peripheral Vascular Diseases
1
2014
102
0.020
Why?
Mood Disorders
1
2014
130
0.020
Why?
Socioeconomic Factors
1
2018
1327
0.020
Why?
Drug Utilization Review
1
2013
60
0.020
Why?
Myocardium
1
2018
948
0.020
Why?
Acute Disease
1
2015
1038
0.020
Why?
Propensity Score
1
2014
376
0.020
Why?
Atenolol
1
2012
8
0.020
Why?
Biopsy
1
2015
1075
0.020
Why?
Nebivolol
1
2012
9
0.020
Why?
Metoprolol
1
2012
26
0.020
Why?
Propanolamines
1
2012
40
0.020
Why?
Carbazoles
1
2012
53
0.020
Why?
Risk
1
2014
920
0.020
Why?
Decision Making
1
2019
993
0.020
Why?
Matched-Pair Analysis
1
2011
38
0.020
Why?
Duloxetine Hydrochloride
1
2011
10
0.020
Why?
Venlafaxine Hydrochloride
1
2011
12
0.020
Why?
Nervous System Diseases
1
2014
288
0.020
Why?
Cetuximab
1
2011
110
0.020
Why?
Sitagliptin Phosphate
1
2011
31
0.020
Why?
Tablets
1
2010
41
0.020
Why?
State Medicine
1
2009
23
0.020
Why?
Epidemiologic Methods
1
2009
91
0.020
Why?
Length of Stay
1
2015
1358
0.020
Why?
Critical Care
1
2015
706
0.020
Why?
Injections, Subcutaneous
1
2009
170
0.020
Why?
Blood Glucose
2
2011
2360
0.020
Why?
Maximum Tolerated Dose
1
2009
217
0.020
Why?
Insurance Coverage
1
2010
248
0.020
Why?
United Kingdom
1
2009
377
0.020
Why?
Odds Ratio
1
2011
1077
0.020
Why?
Probability
1
2009
309
0.020
Why?
Statistics, Nonparametric
1
2009
426
0.020
Why?
Confidence Intervals
1
2008
329
0.020
Why?
Canada
1
2009
432
0.020
Why?
Reference Values
1
2009
796
0.020
Why?
Sex Distribution
1
2008
382
0.020
Why?
Longitudinal Studies
1
2014
3017
0.020
Why?
Prognosis
1
2015
4351
0.020
Why?
Models, Biological
1
2014
1761
0.010
Why?
Analysis of Variance
1
2009
1298
0.010
Why?
RNA, Messenger
1
2013
2791
0.010
Why?
Tomography, X-Ray Computed
1
2015
2786
0.010
Why?
Health Status Disparities
1
2008
322
0.010
Why?
Child, Preschool
2
2007
11913
0.010
Why?
Emergency Medical Services
1
2007
680
0.010
Why?
Risk Assessment
1
2009
3712
0.010
Why?
Body Mass Index
1
2007
2458
0.010
Why?
Infant, Newborn
1
2006
6460
0.010
Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)